These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21975775)

  • 1. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007927. PubMed ID: 21975775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor blockers for the treatment of ovarian cancer.
    Morrison J; Thoma C; Goodall RJ; Lyons TJ; Gaitskell K; Wiggans AJ; Bryant A
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD007927. PubMed ID: 30321910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiogenesis inhibitors for the treatment of ovarian cancer.
    Gaitskell K; Martinek I; Bryant A; Kehoe S; Nicum S; Morrison J
    Cochrane Database Syst Rev; 2011 Sep; (9):CD007930. PubMed ID: 21901715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
    Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Wiggans AJ; Cass GK; Bryant A; Lawrie TA; Morrison J
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD007929. PubMed ID: 25991068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
    Lawrie TA; Bryant A; Cameron A; Gray E; Morrison J
    Cochrane Database Syst Rev; 2013 Jul; 2013(7):CD006910. PubMed ID: 23835762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
    Wuntakal R; Seshadri S; Montes A; Lane G
    Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon after surgery for women with advanced (Stage II-IV) epithelial ovarian cancer.
    Lawal AO; Musekiwa A; Grobler L
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD009620. PubMed ID: 23740789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical cytoreduction for recurrent epithelial ovarian cancer.
    Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
    Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal primary surgical treatment for advanced epithelial ovarian cancer.
    Elattar A; Bryant A; Winter-Roach BA; Hatem M; Naik R
    Cochrane Database Syst Rev; 2011 Aug; 2011(8):CD007565. PubMed ID: 21833960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation.
    Edwards SJ; Barton S; Thurgar E; Trevor N
    Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Lawrie TA; Winter-Roach BA; Heus P; Kitchener HC
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD004706. PubMed ID: 26676202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant (post-surgery) chemotherapy for early stage epithelial ovarian cancer.
    Winter-Roach BA; Kitchener HC; Lawrie TA
    Cochrane Database Syst Rev; 2012 Mar; 3(3):CD004706. PubMed ID: 22419298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
    Lorusso D; Hilpert F; González Martin A; Rau J; Ottevanger P; Greimel E; Lück HJ; Selle F; Colombo N; Kroep JR; Mirza MR; Berger R; Pardo B; Grischke EM; Berton-Rigaud D; Martinez-Garcia J; Vergote I; Redondo A; Cardona A; Bastière-Truchot L; du Bois A; Kurzeder C;
    Int J Gynecol Cancer; 2019 Sep; 29(7):1141-1147. PubMed ID: 31420414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated liposomal doxorubicin for first-line treatment of epithelial ovarian cancer.
    Lawrie TA; Rabbie R; Thoma C; Morrison J
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD010482. PubMed ID: 24142521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    Makhija S; Amler LC; Glenn D; Ueland FR; Gold MA; Dizon DS; Paton V; Lin CY; Januario T; Ng K; Strauss A; Kelsey S; Sliwkowski MX; Matulonis U
    J Clin Oncol; 2010 Mar; 28(7):1215-23. PubMed ID: 19901115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA-repair pathway inhibitors for the treatment of ovarian cancer.
    Martinek I; Haldar K; Gaitskell K; Bryant A; Nicum S; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2010 Jun; (6):CD007929. PubMed ID: 20556786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.